Related references
Note: Only part of the references are listed.A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia
Amir Enshaei et al.
BLOOD (2020)
Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children?s Oncology Group Trial AALL0331
Kelly W. Maloney et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols
Alexander Popov et al.
LEUKEMIA (2020)
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study
Rob Pieters et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG
Michael J. Burke et al.
HAEMATOLOGICA (2019)
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
Giovanni Cazzaniga et al.
HAEMATOLOGICA (2018)
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
Giovanni Cazzaniga et al.
HAEMATOLOGICA (2018)
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)
Martin Schrappe et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia
Michael N. Dworzak et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2018)
Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL
M. Kotrova et al.
BONE MARROW TRANSPLANTATION (2017)
Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group
Rob Pieters et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study
Martin Schrappe et al.
BLOOD (2011)
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study
Valentino Conter et al.
BLOOD (2010)
Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol
V. H. J. Van der Velden et al.
LEUKEMIA (2009)
Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring
V. H. J. van der Velden et al.
LEUKEMIA (2008)
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial
Rob Pieters et al.
LANCET (2007)
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
V. H. J. van der Velden et al.
LEUKEMIA (2007)
Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations
T Burmeister et al.
LEUKEMIA (2006)
Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias
AH Li et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Diagnostic tool for the identification of MLL rearrangements including unknown partner genes
C Meyer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Share Paper
